Treatment Considerations in Special Populations – BC1
This session, targeted to the experienced oncology pharmacist, discusses treatment considerations and examines available evidence for special populations of oncology patients including rural patients with challenges in access to cancer care; pregnant patients with sometimes disparate concerns of safety of the fetus and adequate treatment of the cancer; patients with organ dysfunction in cases where good evidence for safe and effective dosing is lacking; amputees and the challenges of calculating their doses; and the obese patient population, which is continuing to increase in number and degree of obesity, and the challenges of safely and effectively treating their cancer.
- Apply data for safe chemotherapy use during pregnancy to the dosing of chemotherapy and selection of treatment plans in this patient population.
- Analyze recommendations for dosing of chemotherapy in the obese patient population.
- Describe strategies for improving chemotherapy management in the rural patient population.
Mary Mably, RPh BCOP
Mary Mably received her BS in pharmacy from St. Louis College of Pharmacy in 1983. She has worked for UW Health in Madison, WI, since 2008, where she is supervisor of oncology pharmacy programs and PGY2 oncology pharmacy residency program director. She has been board certified in oncology pharmacy since 2002. She currently serves on the institution’s Pharmacy Oncology Service Line Committee, Chemotherapy Review Council, Molecular Tumor Board, Pharmaceutical Review and Monitoring Committee, and Oncology Practice Committee. She was honored to receive the UW Health Pharmacy Department Preceptor of the Year Award in 2015. She has served on multiple HOPA committees and workgroups.
Cancer Prevention: How to Protect Your Patients – BC2
This BCOP session focuses on cancer prevention information and methods. The presentation begins with background on cancer prevention, including understanding of risk factors associated with cancer, prevention concepts, and a review of all cancers that have known prevention methods. Next it will review the national guidelines regarding cancer prevention and the data to support them, followed by discussion of known nonpharmacologic, pharmacologic and therapeutic prevention methods and the data showing their impact on cancer prevention, morbidity, and mortality.
- Identify which cancers have direct preventative methods, associated/indirect preventative methods, or no known preventative methods.
- Illustrate appropriate use of national guidelines for cancer prevention methods and recommendations.
- Consider applicable cancer prevention methods in the context of therapeutic and nontherapeutic options.
Robert Mancini, PharmD BCOP
Robert Mancini is a clinical oncology pharmacist and PGY-2 oncology pharmacy residency program director at St. Luke’s Mountain States Tumor Institute and a clinical adjunct instructor in Oncology at Idaho State University. He has spoken at local, regional, and national conferences on a variety of topics related to cancer care, including supportive care, new drugs in oncology, and oral chemotherapy, and has written numerous publications on these topics. He has spoken at two previous HOPA annual conferences and has served on the HOPA Needs Assessment Committee as a member, vice-chair, and chair for the last 4 years.
Management of Young Patients with Breast Cancer – BC3
Young patients with breast cancer present with unique concerns related to the treatment of their malignancy and management of toxicities. This session will review important considerations, such as premature menopause, fertility, and bone health, in the treatment of young patients with breast cancer. In addition, recent updates regarding treatment options for adjuvant endocrine therapy in premenopausal women will be presented.
- Recognize treatment-related concerns in young patients with breast cancer.
- Discuss the management of treatment-related toxicities in young patients with breast cancer.
- Compare the treatment of breast cancer in young patients with that in older patients.
Neelam Patel, PharmD BCOP
Neelam Patel is a clinical pharmacy specialist at MD Anderson Cancer Center and has been practicing in breast medical oncology since July 2012. She obtained her PharmD degree from Mercer University’s College of Pharmacy and Health Sciences in 2010 and completed her PGY-1 pharmacy residency at Memorial University Medical Center in Savannah, GA, and her PGY-2 oncology pharmacy residency at the University of Texas MD Anderson Cancer Center.
Update on Aplastic Anemia – BC4
The presenter will review practice guidelines and new therapies for the management and treatment of aplastic anemia.
- Consider the role of eltrombopag in the treatment of aplastic anemia.
- Explore the data for the role of stem cell transplantation in the treatment of aplastic anemia.
- Consider outcomes for matched related versus matched unrelated donors.
LeAnne Kennedy, PharmD BCOP CPP FHOPA
LeAnne Kennedy is a pharmacy clinical specialist for stem cell transplant at Wake Forest Baptist Health in Winston Salem, NC, where she is also the director of the PGY-2 oncology residency. She graduated from Campbell University School of Pharmacy in 1993 and then completed a pharmacy practice residency. She received board certification in oncology in 2002 and her clinical pharmacy practitioner license in 2013. She was recognized as one of the first Fellows of HOPA in 2016.
Dysregulation of Water and Sodium: Implications and Management in Pediatric Cancer Patients – BC5
In this session all attendees will participate in a review of dynatremias and water and sodium homeostasis (including the function of water. sodium, and antidiuretic hormone and the regulation of plasma osmolality); an evaluation of a dysnatremic patient; a review of the etiology, clinical manifestations, and management of hypernatremia; and a review of the etiology, clinical manifestations, and management of hyponatremia with 3% saline/vaptans. In addition, beginning and advanced practitioners will look at the dysnatremias seen in pediatric cancer patients (cerebral salt wasting, syndrome of inappropriate antidiuretic hormone secretion, and seizures.
- Review the pathophysiology of water and sodium homeostasis.
- Review the etiology, clinical manifestations, and management of hypo- and hypernatremia.
- Identify dysnatremias encountered in pediatric cancer patients: cerebral salt wasting, diabetes insipidus, and syndrome of inappropriate antidiuresis.
Deborah Ward, PharmD BCOP BCPS
Deborah Ward worked as an analytical developmental chemist in the pharmaceutical industry after graduating from St. Joseph’s University with a chemistry degree. She earned her BS and PharmD degrees from Temple University School of Pharmacy and completed postgraduate training with a pharmacy practice residency at Shands Hospital at University of Florida–Gainesville and a clinical fellowship in hematology/oncology at VCU/MCV in Richmond, VA. She has been a clinical pharmacy specialist in pediatric hematology/oncology at St. Jude Children’s Research Hospital for more than 15 years, with a primary focus on solid tumor and neurooncology, pain, and palliative care.
Applications of Immunotherapy in Pediatric Oncology – BC6
This session will focus on immune-based therapies with an emphasis on the use of monoclonal antibody treatments in pediatric oncology. The tumor microenvironment as well as the interaction between cancer cells and the immune system will be reviewed. Emphasis will be given to the application of these concepts to advance the use of monoclonal antibody therapy in selected pediatric cancers, including neuroblastoma, pediatric leukemias, pediatric melanoma, and other relapsed and refractory pediatric solid tumors.
- Discuss cellular components and their respective roles in the tumor microenvironment.
- Outline the cancer immunity cycle.
- Examine advances in immunotherapy-driven targeted monoclonal antibodies in the treatment of pediatric cancers.
Alina Barnett, PharmD BCPS
Alina Barnett is an outpatient pediatric clinical pharmacist at Seattle Children’s Hospital. She graduated from Washington State University School of Pharmacy in 2007. She is an experienced clinical pediatric pharmacy specialist who is dedicated to her patients, her team and the continuing education of pharmacy. For nearly a decade she has been practicing in inpatient pediatric oncology and bone marrow transplant at UCSF Benioff Children’s Hospital and outpatient bone marrow transplant at Seattle Children’s Hospital.
Bone-Modifying Agents for the Treatment and Prevention of Skeletal-Related Events and Hypercalcemia – BC7
This session will review the newest literature on the treatment of hypercalcemia, including the use denosumab, and discuss the use of denosumab and bisphosphonates for the prevention of skeletal-related events in solid tumors and multiple myeloma. Dosing, dosing interval, length of therapy, and adverse-events management will also be reviewed.
- Examine the role of denosumab in the treatment of hypercalcemia of malignancy.
- Analyze the data for using bisphosphonate for the prevention of skeletal-related events in patients with bone metastases from solid tumors and multiple myeloma.
- Recommend an appropriate monitoring plan for the management and prevention of adverse events associated with the use of bone modifying agents.
Jennifer Davis, PharmD BCOP
Jennifer Davis is an outpatient clinical specialist for Community Health Network in Indianapolis, IN. She has had experience working in inpatient bone marrow transplantation at the University of Pennsylvania and with outpatients at Indiana University Health. She works closely with the oncology team to ensure safe delivery of all chemotherapy, including the recent development of an oral oncology program.
Updates on Management of Immune Thrombocytopenic Purpura – BC8
This session will review literature on ITP, including current frontline and second-line treatment strategies. Focus will be on interpreting data from the newer therapy options, including romiplostim and eltrombopag. Recent literature evaluating the longer-term safety and efficacy of these agents, both pre- and postsplenectomy, will be discussed.
- Compare the efficacy of appropriate therapy options for Immune Thrombocytopenic Purpura (ITP).
- Interpret the safety data regarding the various treatment options for ITP.
- Recommend therapy management instructions for patients on Thrombopoietin Receptor Agonists (TPO-RA).
Brian Cochran, PharmD BCOP
Brian Cochran is an oncology pharmacy specialist at Community Health Network in Indianapolis, IN. He received his PharmD degree from Purdue University. After completing his PGY-1 residency, he served as the first PGY-2 oncology resident for Clarian Health Partners (now IU Health). Career highlights include creating a new inpatient/outpatient oncology pharmacy role at Ball Memorial Hospital, serving as the first outpatient oncology pharmacy coordinator at IU Health, and serving in a newly created oncology clinical specialist role with Community Health Network. He enjoys team-oriented work toward improving the lives of those with cancer.